WILMINGTON, Del., April 18, 2016 -- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against AMC Networks, Inc. (“AMC Networks” or the “Company”).
If you currently own shares of AMC Networks and want to receive additional information and protect your investments free of charge, please visit us at http://www.andrewsspringer.com/cases-investigations/amc-networks-class-action-investigation or contact Craig J. Springer, Esq. at [email protected], or call toll free at 1-800-423-6013. You may also follow us on LinkedIn – www.linkedin.com/company/andrews-&-springer-llc, Twitter – www.twitter.com/AndrewsSpringer or Facebook - www.facebook.com/AndrewsSpringer for future updates.
Andrews & Springer is a boutique securities class action law firm representing shareholders nationwide who are victims of securities fraud, breaches of fiduciary duty or corporate misconduct. Having formerly defended some of the largest financial institutions in the world, our founding members use their valuable knowledge, experience, and superior skill for the sole purpose of achieving positive results for investors. These traits are the hallmarks of our innovative approach to each case our Firm decides to prosecute. For more information please visit our website at www.andrewsspringer.com. This notice may constitute Attorney Advertising.
Contact: Craig J. Springer, Esq. [email protected] Toll Free: 1-800-423-6013


FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 



